



# Expression and Prognostic Value of *RAD51* in Adenocarcinoma at the Gastroesophageal Junction

Darebai Redati, Xinhui Yang, Cheng Lei, Lin Liu, Lei Ge, \*Haijiang Wang

Department of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, China

\*Corresponding Author: Email: frank80828@163.com

(Received 09 Feb 2022; accepted 22 Apr 2022)

## Abstract

**Background:** The *RAD51* recombinase is involved in homologous recombination and DNA repair. However, the association of *RAD51* with the prognosis of adenocarcinoma at the gastroesophageal junction (ACGEJ) is not clear. We aimed to investigate the association of *RAD51* with ACGEJ prognosis.

**Methods:** The difference in the expression level of *RAD51* between ACGEJ tumors and control tissues in the microarray datasets (GSE159721, GSE74553, and GSE96669) were compared. The online Kaplan-Meier plotter survival analysis and meta-analysis were used to analyze the association of *RAD51* with overall survival in pan-cancers. MiRNAs targeting *RAD51* were identified and their expression profiles in ACGEJ tumors were analyzed. Functional enrichment analysis was performed for miRNAs of *RAD51*.

**Results:** *RAD51* was upregulated in ACGEJ tumors compared with control tissues ( $P < 0.05$ ). High *RAD51* level was correlated with a poor prognosis in stomach adenocarcinoma and esophageal cancer. The meta-analysis showed that high *RAD51* level was correlated with a poor prognosis in TCGA pan-cancers ( $P = 0.03$ ). Six regulatory miRNAs of *RAD51*, including *hsa-miR-182*, *hsa-miR-221*, and *hsa-miR-34a*, were downregulated in ACGEJ tumor tissues and were associated with pathways including “fatty acid biosynthesis” and “viral carcinogenesis”.

**Conclusions:** *RAD51* is a potent prognostic biomarker in ACGEJ. MiRNAs including *hsa-miR-182*, *hsa-miR-221*, and *hsa-miR-34a* might play crucial roles in ACGEJ by regulating the *RAD51* gene.

**Keywords:** Gastroesophageal junction adenocarcinoma; *RAD51* recombinase; microRNAs; The Cancer Genome

## Introduction

Gastric cancer is one of the most commonly diagnosed cancer worldwide (1,2). Also, the incidence of adenocarcinoma at the gastroesophageal junction (ACGEJ) has increased rapidly over the past few decades (3). The reason why ACGEJ remains a malignancy of great interest because there are many risk factors, such as smoking, obesity, and gastroesophageal reflux (3). ACGEJ

is divided into three subtypes (Siewert type I, II, and III) according to the Siewert classification and proximal/distal of the anatomic gastric cardia and the overall survival of the three subtypes were different.

The prognosis of ACGEJ is related to several factors, including the extent of nodal involvement (4,5), human epidermal growth factor re-



ceptor 2 (*HER2*) status (6), neoadjuvant chemotherapy, and surgical strategy (7,8). More numbers of resected lymph nodes were associated with better survival in Siewert type II ACGEJ patients (5). Also, there is a controversy on the prognostic role of *HER2* status in ACGEJ patients (6,9). Genetic factors including microRNAs and genes are biomarkers associated with the diagnosis or prognosis of ACGEJ (10,11). The discovery of new biomarkers plays an important role in an early, rapid, and accurate determination of disease occurrence and prognosis of human cancers.

The *RAD51* recombinase is a RecA-like recombination and DNA repair protein involved in homologous recombination and DNA repair (12,13). The RAD51 protein interacts with the ssDNA-binding protein RPA and the RAD52 protein for the homologous pairing and strand transfer of DNA (12,13); and interacts with proteins BRCA1 and BRCA2 to play roles in responses to DNA damage (14,15). The stable recruitment of RAD51 to double-strand breaks is dependent on proteins including the RAD51 paralogs and *BRC A1/2* (16). Cediranib-induced tumor hypoxia suppressed the expression of the homology-directed DNA repair factors including *BRC A1/2* and *RAD51*, and then conferred sensitivity to olaparib in tumor cells (17). Recent studies showed that the *RAD51* gene is a potential prognostic marker for multiple tumors, including colorectal adenocarcinoma (COAD) (18), hepatocellular carcinoma (HCC) (19), breast cancer (BRCA) (20), and colorectal cancer (CRC) (21). However, evidence showing the association of the *RAD51* gene with ACGEJ prognosis is lacking.

Advances in microarray dataset, sequencing technology, and The Cancer Genome Atlas (TCGA) program promote the discovery of diagnostic and prognostic biomarkers contributing to the early, rapid, and accurate determination of tumor development and prognosis. We aimed to evaluate the association of the *RAD51* gene with ACGEJ prognosis using microarray datasets and TCGA program. The regulatory microRNAs (miRNAs) of *RAD51* were also identified to detect the po-

tential miRNA-*RAD51* regulatory axes related to ACGEJ prognosis.

## Materials and Methods

### *Microarray datasets*

This is a bioinformatics analysis based on gene expression microarray datasets conducted in 2021. Gene expression microarray datasets (GSE159721, GSE74553, and GSE96669) of ACGEJ were downloaded from the National Center of Biotechnology Information Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) on October 10, 2021. The datasets were selected because they included  $\geq 50$  ACGEJ tumor samples and the adjacent non-tumor tissue samples. The GSE159721 dataset (GPL20795, HiSeq X Ten [Homo sapiens]) included 123 ACGEJ tumor samples and 123 paired adjacent non-tumor tissue samples. The GSE96669 dataset (GPL10558, Illumina HumanHT-12 V4.0 expression beadchip) consisted of 121 ACGEJ tumor samples and 11 non-cancer control samples. The GSE74553 dataset (GPL17692, [HuGene-2\_1-st] Affymetrix Human Gene 2.1 ST Array [transcript (gene) version]) included 70 ACGEJ tumor samples and 13 normal esophageal squamous and gastric mucosa sections.

### *Data processing and RAD51 expression*

The expression level of the *RAD51* gene in the three datasets were downloaded and extracted from the GSE159721, GSE74553, and GSE96669 datasets. The difference in the expression level of *RAD51* between the tumor and control samples was compared. Moreover, the expression profiles of the *RAD51* gene across TCGA pan-cancers were determined in the UALCAN web resource (<http://ualcan.path.uab.edu/index.html>).

### *RAD51-related genes and protein-protein interaction (PPI) network*

The PPI pairs related to the *RAD51* gene were screened in the STRING database (Version 10.0;

<http://www.string-db.org/>) with the cutoff value of a score  $> 0.4$ . Genes related to the *RAD51* gene were identified and used for the functional enrichment analysis. The Cytoscape software (version: 3.6.0, <http://www.cytoscape.org/>) was used to construct the PPI network.

### **Functional enrichment analysis for *RAD51***

Functional enrichment analysis of the Gene Ontology (GO) biological process and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to the genes related to the *RAD51* gene was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, version 6.8; <https://david.ncifcrf.gov/>). The items significantly associated with *RAD51*-related genes were selected using the criteria of  $p < 0.05$  and count  $\geq 2$ .

### **Overall survival analysis for the *RAD51* gene**

The Kaplan-Meier plotter (<https://kmplot.com/analysis/index.php?p=service>) is a meta-analysis-based discovery and validation of survival biomarkers based on the GEO, European Genome-phenome Archive (EGA), and TCGA databases. The probabilities of *RAD51* with overall survival in 21 cancers, including breast, ovarian, lung, and gastric cancer, were assessed using the Kaplan-Meier plotter with automatically selected best cutoffs.

### **Identification of miRNAs targeting *RAD51***

The regulatory miRNAs of the *RAD51* gene were identified from five databases, including starbase (pancancerNum  $\geq 10$ ; <http://starbase.sysu.edu.cn/>), TargetScan (context++ score percentile  $\geq 99$ ; [http://www.targetscan.org/vert\\_71/](http://www.targetscan.org/vert_71/)), miRDB (Target Score  $\geq 75$ ; <http://www.mirdb.org/>), mirDIP (Score Class = High; <http://ophid.utoronto.ca/mirDIP/>), and miRmap (score  $> 75$ ; <https://mirmap.ezlab.org/app/>). MiRNAs in at least three databases were obtained using the Venn map (<http://bioinformatics.psb.ugent.be/webtools/Venn/>)

and were the key regulatory miRNAs of *RAD51*. Also, the experimentally validated miRNAs targeting *RAD51* were identified from the published studies in PubMed, Medline, and Web of Science. The differences in the expression levels of the key regulatory miRNAs between the ACGEJ tumor samples and non-tumor samples in the microarray datasets were analyzed.

### **Functional enrichment analysis for miRNAs**

The DIANA-miRPath v3.0 (<http://www.microrna.gr/miRPathv3>) is an online miRNA pathway analysis web-server dedicated to the assessment of miRNA regulatory roles and the identification of controlled pathways. We used the DIANA-miRPath to identify the pathways related to the regulatory miRNAs of *RAD51* based on the predicted miRNA targets provided by the experimentally validated miRNA interactions derived from DIANA-TarBase.

### **Statistical analysis**

The statistical analysis was performed in the SPSS 22.0 software (IBM SPSS, IBM, Armonk, NY, USA) and the Review Manager (RevMan version 5.0; Cochrane Collaboration, Oxford, UK). The differences in the expression levels of the *RAD51* gene and related miRNAs between groups were compared using the non-parametric Mann-Whitney U test. A meta-analysis was performed to evaluate the probability of the *RAD51* gene for predicting the prognosis of cancers. The cutoff value for the significant difference was set at  $P < 0.05$ .


## **Results**

### ***RAD51* is upregulated in ACGEJ tumors**


The *RAD51* gene is upregulated in ACGEJ tumor samples compared with the non-tumor control samples in the datasets GSE159721 ( $P = 5.93E-29$ ), GSE74553 ( $P = 8.18E-06$ ), and GSE96669 ( $P = 1.61E-04$ ; Fig. 1). We found the expression levels of the *RAD51* gene were upregulated in several other human cancer tissues

compared with control, including BRCA, esophageal cancer/esophageal squamous cell carcinoma

(ESCA), HCC, and stomach adenocarcinoma (STAD,  $P < 0.05$ ; Fig. 2).



**Fig. 1:** The expression level of the *RAD51* gene in the GSE159721, GSE74553, and GSE96669 datasets. The differences in the expression levels of the *RAD51* gene between groups were analyzed using the non-parametric Mann-Whitney U test. TPM, transcripts per million. FPKM, fragments per kilobase of transcript per million fragments sequenced




**Fig. 2:** Bar plot of *RAD51* expression profile across all tumor samples and paired normal tissues in the TCGA platform. TPM, transcripts per million. BLCA, bladder cancer. BRCA, breast cancer. CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma. CHOL, cholangiocarcinoma. COAD, Colon adenocarcinoma. ESCA, esophageal squamous cell carcinoma. GBM, glioblastoma multiforme. HNSC, head and neck squamous cell carcinoma. KICH, kidney chromophobe. KIRC, kidney renal clear cell carcinoma. KIRP, kidney renal papillary cell carcinoma. LIHC/HCC, liver hepatocellular carcinoma. LUAD, lung adenocarcinoma. LUSC, lung squamous cell carcinoma. PAAD, pancreatic adenocarcinoma. PCPG, pheochromocytoma and paraganglioma. PRAD, prostate adenocarcinoma. READ, rectum adenocarcinoma. SARC, sarcoma. SKCM, skin cutaneous melanoma. STAD, stomach adenocarcinoma. THCA, thyroid carcinoma. THYM, thymoma. UCEC, uterine corpus endometrial carcinoma


**Survival analysis for the *RAD51* gene in human cancers**

We assessed the probability of the *RAD51* as a prognostic biomarker in human pan-cancers using the Kaplan-Meier plotter. We found that the *RAD51* gene might be a prognostic biomarker in multiple types of human cancers, including esophageal adenocarcinoma (EAC; hazard ratio, HR=2.30, logrank  $P = 0.042$ ), ESCA (HR=0.40,

logrank  $P = 0.032$ ), and STAD (HR=0.68, logrank  $P = 0.018$ ; Fig. 3). For instance, EAC, HCC, and BRCA patients who had high expression levels of *RAD51* had low survival probabilities compared with patients who had low expression levels of *RAD51*. A meta-analysis showed that the high expression level of the *RAD51* gene was a risk factor for the poor prognosis of pan-cancers ( $P = 0.03$ , Fig. 4).



**Fig. 3: Kaplan-Meier plotter analysis of the *RAD51* gene.** BRCA, breast cancer. EAC, esophageal adenocarcinoma. ESCA, esophageal squamous cell carcinoma. LIHC/HCC, liver hepatocellular carcinoma. LUAD, lung adenocarcinoma. STAD, stomach adenocarcinoma. Differences between groups were analyzed using the logrank test. Samples are divided into high and low expression group according to the median expression levels of the *RAD51* gene in the corresponding cancer



**Fig. 4: The meta-analysis for the *RAD51* gene of pan-cancer prognosis.** IV, inverse variance. SE, standard error. CI, confident interval. BLCA, bladder cancer. BRCA, breast cancer. CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma. EAC, esophageal adenocarcinoma. ESCA, esophageal squamous cell carcinoma. HNSC, head and neck squamous cell carcinoma. KIRC, kidney renal clear cell carcinoma. KIRP, kidney renal papillary cell carcinoma. LIHC/HCC, liver hepatocellular carcinoma. LUAD, lung adenocarcinoma. LUSC, lung squamous cell carcinoma. OVC, ovarian cancer. PAAD, pancreatic adenocarcinoma. READ, rectum adenocarcinoma. SARC, sarcoma. STAD, stomach adenocarcinoma. THCA, thyroid carcinoma. UCEC, uterine corpus endometrial carcinoma

**RAD51-related genes and the PPI network**


Ten genes related to the RAD51 gene were identified from the STRING database (Fig. 5A). All the ten genes were upregulated in ACGEJ tumor samples compared with the non-tumor control samples in the GSE159721 dataset ( $P < 0.05$ , Fig. 5B). Functional enrichment analysis showed that the gene cluster was associated with 35 biological

processes, including “GO:0006281: DNA repair”, “GO:0042127: regulation of cell proliferation”, and “GO: 0034599:cellular response to oxidative stress”, and four KEGG pathways, including “hsa03460: Fanconi anemia pathway”, “hsa03440: Homologous recombination”, “hsa05200: Pathways in cancer”, and “hsa05212: Pancreatic cancer” (Table 1).

**Table 1:** The results of functional enrichment analysis for the RAD51 gene and related genes

<i>Term</i>	<i>No</i>	<i>P value</i>	<i>Genes</i>
Gene Ontology biological processes (top 20)			
GO:0000724:double-strand break repair via homologous recombination	7	1.23E-12	RAD51AP1, BLM, RAD51, RPA1, BRCA1, BRCA2, PALB2
GO:0000732:strand displacement	6	1.48E-12	RAD51AP1, BLM, RAD51, BRCA1, BRCA2, PALB2
GO:0000731:DNA synthesis involved in DNA repair	6	7.30E-12	RAD51AP1, BLM, RAD51, BRCA1, BRCA2, PALB2
GO:0006281:DNA repair	7	1.41E-09	RAD52, RAD51AP1, BLM, RAD51, CHEK1, RPA1, BRCA1
GO:0006974:cellular response to DNA damage stimulus	6	6.66E-08	RAD52, BLM, RAD51, CHEK1, ABL1, BRCA1
GO:0006310:DNA recombination	5	1.14E-07	RAD52, BLM, RAD51, RPA1, BRCA1
GO:0031052:chromosome breakage	3	3.19E-06	BRCA1, BRCA2, PALB2
GO:0006302:double-strand break repair	4	6.82E-06	RAD52, MND1, BRCA1, BRCA2
GO:0001833:inner cell mass cell proliferation	3	2.10E-05	CHEK1, BRCA2, PALB2
GO:0010569:regulation of double-strand break repair via homologous recombination	3	3.81E-05	RAD51AP1, RAD51, CHEK1
GO:0016925:protein sumoylation	4	3.82E-05	RAD52, BLM, RPA1, BRCA1
GO:1901796:regulation of signal transduction by p53 class mediator	4	4.54E-05	BLM, CHEK1, RPA1, BRCA1
GO:0010165:response to X-ray	3	7.33E-05	BLM, RAD51, BRCA2
GO:0006260:DNA replication	4	8.83E-05	BLM, CHEK1, RPA1, BRCA1
GO:0071479:cellular response to ionizing radiation	3	1.47E-04	RAD51AP1, BLM, RAD51
GO:0000722:telomere maintenance via recombination	3	1.57E-04	RAD51, RPA1, BRCA2
GO:0036297:interstrand cross-link repair	3	3.70E-04	RAD51AP1, RAD51, RPA1

GO:1990426:mitotic recombination-dependent replication fork processing	2	1.19E-03	<i>RAD51, BRCA2</i>
GO:0072757:cellular response to camptothecin	2	2.38E-03	<i>BLM, RAD51</i>
GO:0000730:DNA recombinase assembly	2	2.97E-03	<i>RAD52, RAD51</i>
GO:0048478:replication fork protection	2	3.57E-03	<i>BLM, BRCA2</i>
GO:0072711:cellular response to hydroxyurea	2	4.16E-03	<i>BLM, RAD51</i>
GO:0006975:DNA damage induced protein phosphorylation	2	4.76E-03	<i>CHEK1, ABL1</i>
GO:0042127:regulation of cell proliferation	3	5.13E-03	<i>CHEK1, ABL1, BRCA1</i>
GO:0000729:DNA double-strand break processing	2	8.90E-03	<i>BLM, BRCA1</i>
GO:0006978:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	2	9.49E-03	<i>BRCA1, BRCA2</i>
GO:0031572:G2 DNA damage checkpoint	2	1.18E-02	<i>CHEK1, BRCA1</i>
GO:0031297:replication fork processing	2	1.60E-02	<i>BLM, RAD51</i>
GO:0045931:positive regulation of mitotic cell cycle	2	1.66E-02	<i>ABL1, BRCA2</i>
GO:0007131:reciprocal meiotic recombination	2	1.77E-02	<i>RAD51, MND1</i>
GO:0006298:mismatch repair	2	2.07E-02	<i>RPA1, ABL1</i>
GO:0006289:nucleotide-excision repair	2	2.42E-02	<i>RPA1, BRCA2</i>
GO:0008630:intrinsic apoptotic signaling pathway in response to DNA damage	2	2.76E-02	<i>ABL1, BRCA1</i>
GO:0045893:positive regulation of transcription, DNA-templated	3	3.59E-02	<i>BLM, BRCA1, BRCA2</i>
GO:0034599:cellular response to oxidative stress	2	3.75E-02	<i>RAD52, ABL1</i>
<b>KEGG pathways</b>			
hsa03460:Fanconi anemia pathway	6	1.23E-09	<i>BLM, RAD51, RPA1, BRCA1, BRCA2, PALB2</i>
hsa03440:Homologous recombination	5	1.76E-08	<i>RAD52, BLM, RAD51, RPA1, BRCA2</i>
hsa05200:Pathways in cancer	3	7.25E-02	<i>RAD51, ABL1, BRCA2</i>
hsa05212:Pancreatic cancer	2	7.32E-02	<i>RAD51, BRCA2</i>




**Fig. 5: The protein-protein interaction (PPI) network and expression of *RAD51*-related genes.** A, the PPI network of the *RAD51* gene and *RAD51*-related genes. B, the expression profiles of the ten *RAD51*-related genes in the adenocarcinoma at the gastroesophageal junction (ACGEJ) tumor samples and the non-tumor control samples in the GSE159721 dataset. The differences in the expression levels of the ten genes between groups were analyzed using the non-parametric Mann-Whitney U test

#### Key regulatory miRNAs of the *RAD51* gene


Nine key regulatory miRNAs of the *RAD51* gene were identified from databases (Fig. 6), and other 15 experimentally validated miRNAs targeting *RAD51* were identified from online searching. Functional enrichment analysis showed that these

miRNAs were related to multiple pathways (Fig. 7). For instance, *hsa-miR-34a-5p*, *hsa-miR-193b-3p*, and *hsa-miR-103a-3p* were associated a variety of pathways, including “fatty acid biosynthesis”, “viral carcinogenesis”, and “proteoglycans in cancer”.





**Fig. 6:** The Venn diagram showing the key regulatory microRNAs of the *RAD51* gene. The regulatory miRNAs of the *RAD51* gene were identified from five databases, including starbase, TargetScan, miRDB, mirDIP, and miRmap, and miRNA shown in at least three databases, were the key regulatory miRNAs




**Fig. 7:** The functional enrichment analysis result for the microRNAs targeting *RAD51*. The DIANA-miRPath v3.0 (<http://www.microrna.gr/miRPathv3>) was used to identify the pathways related to the regulatory miRNAs of *RAD51* based on the experimentally validated miRNA interactions derived from DIANA-TarBase

### Expression validation of the key regulatory miRNAs

Validation of the key regulatory miRNAs of *RAD51* in microarray datasets showed that six miRNAs, including *hsa-miR-10a*, *hsa-miR-182*, *hsa-miR-1915*, *hsa-miR-221*, *hsa-miR-34a*, and *hsa-miR-*

766, were downregulated in ACGEJ tumor samples compared with the non-tumor control samples in the GSE96669 dataset (Fig. 8). These results indicated that the regulatory miRNAs might play important roles in ACGEJ prognosis and development by regulating *RAD51*.



**Fig. 8:** The expression levels of six microRNAs of the *RAD51* gene in the GSE96669 dataset. The differences in the expression levels of the six miRNAs between groups were analyzed using the non-parametric Mann-Whitney U test

## Discussion

This study showed that the *RAD51* gene was up-regulated in ACGEJ tumor tissues compared with the adjacent non-tumor tissues. The overexpression of *RAD51* was correlated with a poor prognosis in ACGEJ patients. Six miRNAs targeting *RAD51*, including *hsa-miR-10a*, *hsa-miR-182*, *hsa-miR-1915*, *hsa-miR-221*, *hsa-miR-34a*, and *hsa-miR-766*, were downregulated in ACGEJ tumor samples compared with the non-tumor control samples. Also, the regulatory miRNAs of *RAD51* were associated with multiple pathways related to cancers and the metabolism of fatty

acids. These results showed that the *RAD51* gene and miRNAs of *RAD51* might have important roles in the prognosis of ACGEJ.

The *RAD51* recombinase is a DNA repair protein that regulates homologous recombination by interacting with ssDNA-binding protein RPA and RAD52 (12,13). Elevated expression of *RAD51* is related to a decreased chemosensitivity in tumor cells (22-24). The overexpression of *RAD51* was associated with a poor prognosis in neuroblastoma patients and the silencing of *RAD51* increased the chemosensitivity to doxorubicin in human neuroblastoma cells (22). Silencing of the *RPA1* gene reduced the RAD51

recruitment at the DNA lesion site, suppressed DNA repair, and increased the radio-sensitivity in CNE-2R cells (25). Moreover, *miR-506* is a regulator of chemo-sensitivity through suppressing *RAD51*-mediated homologous recombination (24). Our present study showed that the *RAD51* gene and *RAD51*-related genes, including *RP41*, *BRC41/2*, *RAD52*, and *RAD51AP1*, were up-regulated in ACGEJ tumor tissues compared with the adjacent non-tumor tissues. Moreover, the high expression level of the *RAD51* gene was related to poor prognoses in ACGEJ patients and in TCGA pan-cancers. These results revealed that the *RAD51* gene might be used as a prognostic biomarker in ACGEJ.

Among the downregulated regulatory miRNAs of the *RAD51* gene, *hsa-miR-182*, *hsa-miR-221*, *hsa-miR-34a*, and *hsa-miR-766* were associated with the prognosis of a variety of human cancers (26-29). The prognostic values of miRNAs in human cancers are tumor type-dependent (29-35). For instance, *miRNA-182* overexpression resulted in low survival ratios in CRC (29,31) and papillary thyroid carcinoma (30), and a good prognosis in non-small cell lung cancer (32). The upregulation of *miRNA-221* was related to the poor prognosis in glioblastoma (33) and a good prognosis in CRC (34). Chen et al. (35) indicated that the downregulation of *miR-34a* was strongly related to shorter overall survival in patients with cervical cancer. *miR-34a* overexpression resulted in a poor prognosis in COAD (36).

These results showed that the regulatory miRNAs of the *RAD51* gene might have crucial roles in the development of human cancers including ACGEJ.

## Conclusion

The *RAD51* gene was upregulated in the ACGEJ tumor tissues compared with the adjacent non-tumor tissues, and its overexpression was correlated with a poor prognosis in ACGEJ patients. The high expression level of *RAD51* was correlated with a poor prognosis in the TCGA pan-cancers. The regulatory miRNAs of *RAD51*, in-

cluding *hsa-miR-10a*, *hsa-miR-182*, *hsa-miR-1915*, *hsa-miR-221*, *hsa-miR-34a*, and *hsa-miR-766*, might play crucial roles in the development and prognosis of ACGEJ by regulating the *RAD51* gene. However, the important roles of these miRNAs in the development and prognosis of ACGEJ should be validated using preclinical experiments and clinical cohort studies.

## Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Acknowledgements

Fund program: Scientific research project of Special training program for Scientific and technological talents of Xinjiang ethnic minorities Number: 2020D03008.

## Conflict of interest

The authors declare that there is no conflict of interest.

## References

1. Joshi SS, Badgwell BD (2021). Current treatment and recent progress in gastric cancer. *CA Cancer J Clin*, 71(3):264-279.
2. Eusebi LH, Telese A, Marasco G, Bazzoli F, Zagari RM (2020). Gastric cancer prevention strategies: a global perspective. *J Gastroenterol Hepatol*, 35(9):1495-1502.
3. Buas MF, Vaughan TL (2013). Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. *Semin Radiat Oncol*, 23(1):3-9.
4. Pedrazzani C, de Manzoni G, Marrelli D, et al (2007). Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. *J Thorac Cardiovasc Surg*, 134(2):378-385.

5. Lai S, Su T, He X, Lin Z, Chen S (2018). Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer. *Oncotarget*, 9(2):2797-2809.
6. Janjigian Y, Werner D, Pauligk C, et al (2012). Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. *Ann Oncol*, 23(10):2656-2662.
7. Al-Batran S-E, Homann N, Pauligk C, et al (2017). Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. *JAMA Oncol*, 3(9):1237-1244.
8. Kamarajah SK, Phillips AW, Griffiths EA, Ferri L, Hofstetter WL, Markar SR (2021). Esophagectomy or total gastrectomy for Siewert 2 gastroesophageal junction (GEJ) adenocarcinoma? A registry-based analysis. *Ann Surg Oncol*, 28(13):8485-8494.
9. Roy PS, Nyodu T, Hazarika M, et al (2019). Prevalence of *HER2* expression and its correlation with clinicopathological parameters in gastric or gastroesophageal junction adenocarcinoma in North-East Indian population. *APJCP*, 20(4):1139-1145.
10. Song D, Tian J, Hu Y, et al (2020). Identification of biomarkers associated with diagnosis and prognosis of gastroesophageal junction adenocarcinoma—a study based on integrated bioinformatics analysis in GEO and TCGA database. *Medicine*, 99(51):e23605.
11. Odenthal M, Hee J, Gockel I, et al (2015). Serum micro RNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction. *Int J Cancer*, 137(1):230-237.
12. Laurini E, Marson D, Fermeglia A, Aulic S, Fermeglia M, Priel S (2020). Role of *RAD51* and DNA repair in cancer: a molecular perspective. *Pharmacol Ther*, 208:107492.
13. Demeyer A, Benhelli-Mokrani H, Chenais B, Weigel P, Fleury F (2021). Inhibiting homologous recombination by targeting *RAD51* protein. *Biochim Biophys Acta Rev Cancer*, 1876(2):188597.
14. Chen JJ, Silver D, Cantor S, Livingston DM, Scully R (1999). *BRCA1*, *BRCA2*, and *RAD51* operate in a common DNA damage response pathway. *Cancer Res*, 59(7 Supplement):1752s-1756s.
15. Bishara LA, Machour FE, Awwad SW, Ayoub N (2021). NELF complex fosters *BRCA1* and *RAD51* recruitment to DNA damage sites and modulates sensitivity to PARP inhibition. *DNA Repair*, 97:103025.
16. Kolinjivadi AM, Sannino V, de Antoni A, Técher H, Baldi G, Costanzo V (2017). Moonlighting at replication forks—a new life for homologous recombination proteins *BRCA1*, *BRCA2* and *RAD51*. *FEBS Lett*, 591(8):1083-1100.
17. Kaplan AR, Gueble SE, Liu Y, et al (2019). Cediranib suppresses homology-directed DNA repair through down-regulation of *BRCA1/2* and *RAD51*. *Sci Transl Med*, 11(492):eaav4508.
18. Tennstedt P, Fresow R, Simon R, et al (2013). *RAD51* overexpression is a negative prognostic marker for colorectal adenocarcinoma. *Int J Cancer*, 132(9):2118-2126.
19. Xu H, Xiong C, Chen Y, Zhang C, Bai D (2021). Identification of *RAD51* as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma. *Bioengineered*, 12(1):2664-2675.
20. Söderlund K, Skoog L, Fornander T, Askmalms MS (2007). The *BRCA1/BRCA2/RAD51* complex is a prognostic and predictive factor in early breast cancer. *Radiother Oncol*, 84(3):242-251.
21. Li Y, Wang W-y, Xiao J-h, et al (2017). Overexpression of *RAD51* predicts poor prognosis in colorectal cancer: our experience with 54 patients. *PLoS One*, 12(1):e0167868.
22. Xu Y, Chen K, Cai Y, Cheng C, Zhang Z, Xu G (2019). Overexpression of *RAD51* predicts poor prognosis and silencing of *RAD51* increases chemo-sensitivity to doxorubicin in neuroblastoma. *Am J Transl Res*, 11(9):5788.
23. Du L-Q, Wang Y, Wang H, Cao J, Liu Q, Fan F-Y (2011). Knockdown of *RAD51* expression induces radiation-and chemo-sensitivity in osteosarcoma cells. *Med Oncol*, 28(4):1481-1487.
24. Liu G, Xue F, Zhang W (2015). *miR-506*: a regulator of chemo-sensitivity through suppression of the *RAD51*-homologous recombination axis. *Chin J Cancer*, 34(3):1-3.
25. Zhang Z, Huo H, Liao K, et al (2018). RPA1

- downregulation enhances nasopharyngeal cancer radiosensitivity via blocking *RAD51* to the DNA damage site. *Exp Cell Res*, 371(2):330-341.
26. Liu S, Lin Z, Zheng Z, et al (2020). Serum exosomal *microRNA-766-3p* expression is associated with poor prognosis of esophageal squamous cell carcinoma. *Cancer Sci*, 111(10):3881-3892.
  27. Zhang R, Pang B, Xin T, et al (2016). Plasma *miR-221/222* family as novel descriptive and prognostic biomarkers for glioma. *Mol Neurobiol*, 53(3):1452-1460.
  28. Guo J, Liu C, Wang W, et al (2018). Identification of serum *miR-1915-3p* and *miR-455-3p* as biomarkers for breast cancer. *PLoS One*, 13(7):e0200716.
  29. Liu H, Du L, Wen Z, et al (2013). Up-regulation of *miR-182* expression in colorectal cancer tissues and its prognostic value. *Int J Colorectal Dis*, 28(5):697-703.
  30. Yao X-G, Tan Q, Liu P-P, Feng L-J (2019). Tissue *microRNA-182* expression level and its potential prognostic value for papillary thyroid carcinoma. *Int J Clin Exp Pathol*, 12(8):3128-3133.
  31. Rapti S-M, Kontos CK, Papadopoulos IN, Scorilas A (2014). Enhanced *miR-182* transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. *Clin Chem Lab Med*, 52(8):1217-1227.
  32. Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund L-T, Bremnes RM (2014). Stage and tissue-specific prognostic impact of *miR-182* in NSCLC. *BMC Cancer*, 14(1):1-10.
  33. Chen Y-Y, Ho H-L, Lin S-C, Ho TD-H, Hsu C-Y (2018). Upregulation of *miR-125b*, *miR-181d*, and *miR-221* predicts poor prognosis in *MGMT* promoter-unmethylated glioblastoma patients. *Am J Forensic Med Pathol*, 149(5):412-417.
  34. Yuan K, Xie K, Fox J, et al (2013). Decreased levels of *miR-224* and the passenger strand of *miR-221* increase *MBD2*, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. *Gastroenterology*, 145(4):853-864. e859.
  35. Chen A-H, Qin Y-E, Tang W-F, Tao J, Song H-m, Zuo M (2017). *MiR-34a* and *miR-206* act as novel prognostic and therapy biomarkers in cervical cancer. *Cancer Cell Int*, 17(1):63.
  36. Rapti S-M, Kontos CK, Christodoulou S, Papadopoulos IN, Scorilas A (2017). *miR-34a* overexpression predicts poor prognostic outcome in colorectal adenocarcinoma, independently of clinicopathological factors with established prognostic value. *Clin Biochem*, 50(16-17):918-924.